Rogier Caluwé1, Stefaan Vandecasteele2, Bruno Van Vlem1, Cees Vermeer3, An S De Vriese2. 1. Division of Nephrology, OLV Hospital, Aalst, Belgium. 2. Division of Nephrology and Infectious Diseases, AZ St.-Jan Hospital, Brugge, Belgium. 3. VitaK, Maastricht University, EV Maastricht, the Netherlands.
Abstract
BACKGROUND: Haemodialysis patients suffer from accelerated vascular calcification. The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification. Haemodialysis patients have high levels of the inactive form of MGP (desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and may benefit from pharmacological doses of vitamin K2 (menaquinone) to improve the calcification inhibitory activity of MGP. METHODS: To determine the optimal dose of menaquinone-7 (MK-7) for MGP activation, 200 chronic haemodialysis patients were recruited to randomly receive 360, 720 or 1080 µg of MK-7 thrice weekly for 8 weeks. Dp-uc-MGP was measured at baseline and after 8 weeks. Dietary intake of vitamin K1 (phylloquinone) and menaquinone was estimated based on a detailed questionnaire. RESULTS: At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023). MK-7 supplementation dose dependently reduced dp-uc-MGP. The levels decreased by 17, 33 and 46% in the respective groups. Drop-outs were mainly due to gastrointestinal side-effects related to the unpleasant smell of the tablets. CONCLUSIONS: Chronic haemodialysis patients have high levels of inactive MGP, possibly related to a low dietary vitamin K intake. Pharmacological doses of MK-7 dose-dependently reduce dp-uc-MGP. Menaquinone supplementation may be a novel approach to prevent vascular calcifications in chronic haemodialysis patients.
BACKGROUND: Haemodialysis patients suffer from accelerated vascular calcification. The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification. Haemodialysis patients have high levels of the inactive form of MGP (desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and may benefit from pharmacological doses of vitamin K2 (menaquinone) to improve the calcification inhibitory activity of MGP. METHODS: To determine the optimal dose of menaquinone-7 (MK-7) for MGP activation, 200 chronic haemodialysis patients were recruited to randomly receive 360, 720 or 1080 µg of MK-7 thrice weekly for 8 weeks. Dp-uc-MGP was measured at baseline and after 8 weeks. Dietary intake of vitamin K1 (phylloquinone) and menaquinone was estimated based on a detailed questionnaire. RESULTS: At baseline, dp-uc-MGP was not associated with phylloquinone intake (P = 0.92), but correlated inversely with menaquinone intake (P = 0.023). MK-7 supplementation dose dependently reduced dp-uc-MGP. The levels decreased by 17, 33 and 46% in the respective groups. Drop-outs were mainly due to gastrointestinal side-effects related to the unpleasant smell of the tablets. CONCLUSIONS: Chronic haemodialysis patients have high levels of inactive MGP, possibly related to a low dietary vitamin K intake. Pharmacological doses of MK-7 dose-dependently reduce dp-uc-MGP. Menaquinone supplementation may be a novel approach to prevent vascular calcifications in chronic haemodialysis patients.
Authors: An S De Vriese; Rogier Caluwé; Lotte Pyfferoen; Dirk De Bacquer; Koen De Boeck; Joost Delanote; Didier De Surgeloose; Piet Van Hoenacker; Bruno Van Vlem; Francis Verbeke Journal: J Am Soc Nephrol Date: 2019-11-08 Impact factor: 10.121
Authors: Julie Ann Kemp; Livia Alvarenga; Ludmila F M F Cardozo; Lu Dai; Peter Stenvinkel; Paul G Shiels; Tilman M Hackeng; Leon J Schurgers; Denise Mafra Journal: Curr Nutr Rep Date: 2022-09-23
Authors: M Kyla Shea; Kathryn Barger; Sarah L Booth; Jifan Wang; Harold I Feldman; Raymond R Townsend; Jing Chen; John Flack; Jiang He; Bernard G Jaar; Mayank Kansal; Sylvia E Rosas; Daniel E Weiner Journal: Am J Clin Nutr Date: 2022-03-04 Impact factor: 8.472
Authors: M Kyla Shea; Kathleen L Berkner; Guylaine Ferland; Xueyan Fu; Rachel M Holden; Sarah L Booth Journal: Adv Nutr Date: 2021-06-01 Impact factor: 8.701